A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)

NCT02953678 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

71

Enrollment

INDUSTRY

Sponsor class

Conditions

Graft-versus-host Disease (GVHD)

Interventions

DRUG: Ruxolitinib
DRUG: Prednisone or methylprednisolone

Sponsor

Incyte Corporation